Literature DB >> 8504237

Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery.

M Zoppi1, R Oppliger, U Althaus, U Nydegger.   

Abstract

A 53-year-old man with abnormally elevated cold agglutinins was treated successfully by plasma exchange so that he was able to sustain coronary artery surgery and extracorporeal circulation. Two plasma exchanges, consisting in the exchange of one plasma volume with a 5% albumin solution each, were performed in our intensive care unit with careful monitoring of vital parameters. The plasma exchanges resulted in a reduction of the titer of the cold agglutinins and of the thermal amplitude as well. With the exception of postoperative bleeding requiring re-intervention, the patient was successfully operated and could be dismissed on the 16th postoperative day in good condition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504237     DOI: 10.1159/000222800

Source DB:  PubMed          Journal:  Infusionsther Transfusionsmed        ISSN: 1019-8466


  5 in total

1.  Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization.

Authors:  Megan Mullins; Xiaohui Jiang; Lauren C Bylsma; Jon P Fryzek; Heidi Reichert; Evan C Chen; Shivaani Kummar; Adam Rosenthal
Journal:  Blood Adv       Date:  2017-05-19

Review 2.  Treatment of autoimmune hemolytic anemias.

Authors:  Alberto Zanella; Wilma Barcellini
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

3.  Agglutinins and cardiac surgery: a web based survey of cardiac anaesthetic practice; questions raised and possible solutions.

Authors:  S Shah; H Gilliland; G Benson
Journal:  Heart Lung Vessel       Date:  2014

Review 4.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

Review 5.  New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.